المؤلفون: Inês Cosme, Ana Figueiredo, Sara Pinheiro, Valeriano Leite

المصدر: European Thyroid Journal, Vol 13, Iss 4, Pp 1-6 (2024)

مصطلحات موضوعية: incidental, non-incidental, papillary carcinoma, thyroid oncology, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

وصف الملف: electronic resource

Relation: https://etj.bioscientifica.com/view/journals/etj/13/4/ETJ-24-0106.xml; https://doaj.org/toc/2235-0802

URL الوصول: https://doaj.org/article/b43df81230b24ea8b9c523cb246ba037

المؤلفون: Sánchez Ordúz, Olga Liset

المساهمون: Wandurraga Sánchez, Edwin Antonio, Ochoa Vera, Miguel Enrique

المصدر: Repositorio UNAB
Universidad Autónoma de Bucaramanga-UNAB
instacron:Universidad Autónoma de Bucaramanga-UNAB

مصطلحات موضوعية: Quality of life, Radiation, Physiological effect, Calidad de vida, Medicina nuclear, Características clínicas, Efectos secundarios, Health sciences, Thyroid oncology, Thyroid neoplasms, Clinical features, Salivary glands, Medical sciences, Ciencias de la salud, Yodoterapia, Oncológica tiroidea, Efectos fisiológicos, Glándulas salivales, Nuclear medicine, Radiación, Side effects, Iodotherapy, Ciencias médicas, Neoplasias de la tiroides

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______3056::17d22d93a5c8f47bac590fd64ab48539

المؤلفون: Sánchez Ordúz, Olga Liset

المساهمون: Wandurraga Sánchez, Edwin Antonio, Ochoa Vera, Miguel Enrique, https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000898465, https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0001475567, https://scholar.google.es/citations?hl=es&user=_j9J_3EAAAAJ, orcid:0000-0001-9794-9017, orcid:0000-0002-4552-3388, https://www.scopus.com/authid/detail.uri?authorId=36987156500, https://www.scopus.com/authid/detail.uri?authorId=56027001700, https://www.researchgate.net/profile/Miguel_Ochoa7

مصطلحات موضوعية: Neoplasias de la tiroides, Glándulas salivales, Medical sciences, Health sciences, Nuclear medicine, Radiation, Physiological effect, Thyroid oncology, Side effects, Clinical features, Iodotherapy, Thyroid neoplasms, Salivary glands, Quality of life, Ciencias médicas, Medicina nuclear, Radiación, Efectos fisiológicos, Yodoterapia, Calidad de vida, Ciencias de la salud, Oncológica tiroidea, Efectos secundarios, Características clínicas

جغرافية الموضوع: Bucaramanga (Santander, Colombia)

وصف الملف: application/pdf

Relation: 1. Asociación Colombiana de Endocrinología. Consenso colombiano para el diagnóstico y manejo de las enfermedades tiroideas. Acta Med Colomb. 1999;24(4):159-174.; 2. World health organization. GLOBOCAN. GLOBOCAN 2018: estimated cancer incidence, mortality and prevalence worldwide in 2018.; 3. Esposito G. Initial radioiodine administration: When to use it and how to select the dose. Endocrinol Metab Clin North Am. 2014;43(2):385-400. doi:10.1016/j.ecl.2014.02.003.; 4. Hedman C, Djärv T, Strang P, Lundgren CI. Fear of Recurrence and View of Life Affect Health-Related Quality of Life in Patients with Differentiated Thyroid Carcinoma: A Prospective Swedish Population-Based Study. Thyroid 2018 Oct 26. 5. Al-Brahim N, Asa SL. Papillary thyroid carcinoma: An overview. Arch Pathol Lab Med. 2006;130(7):1057-1062. doi:10.4103/0019-509X.63025.; 6. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115(16):3801-3807. doi:10.1002/cncr.24416.; 7. Castro-Jimenez, Miguel; Lopez-Daza D. Estabilidad de la mortalidad por cáncer de tiroides en un país emergente. Rev Salud Pública. 2015;17(1):1-11. doi:http://dx.doi.org/10.15446/rsap.v17n1.42209.; 8. Vaccarella S, Franceschi S, Bray F, Wild C, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016;375(7). doi:10.1056/NEJMp1607866.; 9. Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: Analysis of 1060 cases. J Clin Endocrinol Metab. 2010;95(9):4197-4205. doi:10.1210/jc.2010-0337.; 11. Nóbrega E, Lima P, Ferderle D, Galvão A, Bitencourt V, Vartanian JG. Impact of a systematic radioactive iodine therapy protocol for thyroid cancer. 2013;33(4):180-186.; 12. Silberstein EB, Alavi a., Balon HR, et al. The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0. J Nucl Med. 2012;53(10):1633-1651. doi:10.2967/jnumed.112.105148.; 13. Esposito G. Initial radioiodine administration: When to use it and how to select the dose. Endocrinol Metab Clin North Am. 2014;43(2):385-400. doi:10.1016/j.ecl.2014.02.003.; 14. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009;19(12):1381-1391.; 15. Fard-Esfahani A, Emami-Ardekani A, Fallahi B, et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun. 2014;35(8):808-817. doi:10.1097/MNM.0000000000000132.; 16. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892-2899. doi:10.1210/jc.2005-2838.; 17. Almeida JP, Vartanian JG, Kowalski LP. Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. Arch Otolaryngol Head Neck Surg. 2009;135(4):342-346. doi:10.1001/archoto.2009.16.; 18. Fard-Esfahani A, Farzanefar S, Fallahi B, et al. Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer. Nucl Med Commun. 2012;33(10):1077-1080. doi:10.1097/MNM.0b013e3283570fb8.; 19. Fard-Esfahani A, Gholamrezanezhad A, Mirpour S, et al. Assessment of the accuracy of lacrimal scintigraphy based on a prospective analysis of patients’ symptomatology. Orbit. 2008;27(4):237-241. doi:10.1080/01676830802225046.; 20. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-1214. doi:10.1089/thy.2009.0110.; 21. Luster M, Clarke S, Dietlein M, et al. European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941-1959.; 22. Sioka C, Fotopoulos A. Effects of I-131 therapy on gonads and pregnancy outcome in patients with thyroid cancer. Fertil Steril. 2011;95(5):1552-1559. doi:10.1016/j.fertnstert.2011.01.017.; 23. Wheeler SG, Wipf JE, Staiger TO, Deyo RA, Park L. Official reprint from UpToDate www.uptodate.com 2016 UpToDate. 2016;(table 2):1-18. doi:10.1111/j.1442-200x.2005.02148.x.; 24. Carling T, Udelsman R. Thyroid cancer. Annu Rev Med. 2014;65(October):125-137. doi:10.1146/annurev-med-061512-105739.; 25. Vigneri R, Malandrino P, Vigneri P. The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol. 2015;27(1):1-7. doi:10.1097/CCO.0000000000000148.; 26. Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters : Analysis of 1060 Cases. 2016;95(September 2010):4197-4205. doi:10.1210/jc.2010-0337.; 27. Romero A, Cuervo-Martínez J, Osorio-Arango L, Olaya N. Histological variants and prognostic factors of papillary thyroid carcinoma at the National Cancer Institute of Colombia. Biomedica. 2015;35(3):429-436. doi:10.7705/biomedica.v35i3.2598.; 28. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18(3):784-791. doi:10.1158/1055-9965.EPI-08-0960; 29. Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: Does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg. 2007;31(5):916-923. doi:10.1007/s00268-006-0837-3; 30. Avram AM. Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med. 2012;53(5):754-764. doi:10.2967/jnumed.111.104133.; 31. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015;26(1):thy.2015.0020. doi:10.1089/thy.2015.0020.; 32. Glazer DI, Brown RKJ, Wong KK, Savas H, Gross MD, Avram a. M. SPECT/CT Evaluation of Unusual Physiologic Radioiodine Biodistributions: Pearls and Pitfalls in Image Interpretation. Radiographics. 2013;33(2):397-418. doi:10.1148/rg.332125051.; 33. Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid. 2002;12(2):121-134. doi:10.1089/105072502753522356.; 34. Kita T, Yokoyama K, Higuchi T, et al. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. Ann Nucl Med. 2004;18(4):345-349. doi:15359929; 35. Silberstein E. The treatment of thyroid malignant neoplasms. In: Henkin R, Bova D, Dillehay G, et al., eds. Nuclear Medicine. Philadelphia: Mosby Elsevier; 2006:1576-1588.; 36. ar a b B, andkiewic - unak D, Włoch . uvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: A qualitative review. Endocr Relat Cancer. 2005;12(4):773-803. doi:10.1677/erc.1.00880; 37. Van Nostrand D. Sialoadenitis secondary to 131I therapy for well-differentiated thyroid cancer. Oral Dis. 2011;17(2):154-161. doi:10.1111/j.1601-0825.2010.01726.x.; 38. Helman J, Tumer RJ, Fox PC, Baum BJ. TC- pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl- co-transport system. 1987;79(May):1310-1313.; 39. Grewal RK, Larson SM, Pentlow CE, et al. Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation. J Nucl Med. 2009;50(10):1605-1610. doi:10.2967/jnumed.108.061382.; 40. Esfahani A, Fallahi B, Olamaie R, Eftekhari M, Beiki D, Saghari M. Semi- quantitative assessment of salivary gland function in patients with differentiated thyroid carcinoma after radioiodine-131 treatment. Hell J Nucl Med. 2004;(7):206-209.; 41. Maxon H, Smith H. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990;19(3):685-718.; 42. Solans R, Bosch JA, Galofré P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med. 2001;42(5):738-743. http://www.ncbi.nlm.nih.gov/pubmed/11337569.; 43. Zettinig G, Hanselmayer G, Fueger BJ, et al. Long-term impairment of the lacrimal glands after radioiodine therapy: A cross-sectional study. Eur J Nucl Med. 2002;29(11):1428-1432. doi:10.1007/s00259-002-0969-0.; 44. Burns WR, Zeiger MA. Differentiated thyroid cancer. Semin Oncol. 2010;37(6):557-566. doi:10.1053/j.seminoncol.2010.10.008.; 45. da Fonseca FL, Lunardelli P, Matayoshi S. Obstru????o de vias lacrimais 62 associada ao tratamento radioiodoter??pico de carcinoma de tireoide. Arq Bras Oftalmol. 2012;75(2):97-100. doi:10.1590/S0004-27492012000200005.; 46. Husson O, Haak HR, Oranje WA, Mols F, Reemst PHM, van de Poll-Franse, Lonneke V. Health-related quality of life among thyroid cancer survivors: a systematic review. Clin Endocrinol (Oxf) 2011 Oct; 75(4):544-554.; 47 Gou J, Cheng W, Lei J, Pan Q, You W, Cai M, et al. Health-related quality-of-life assessment in surgical patients with papillary thyroid carcinoma: A single-center analysis from Mainland China. Medicine (Baltimore) 2017 Sep;96(38):e8070.; 48. Nazar G, Garmendia ML, Royer M, McDowell JA, Weymuller EA Jr et al. Spanish validation of the University of Washington Quality of Life questionnaire for head and neck cancer patients. Otolaryngol Head Neck Surg. 2010 Dec;143(6):801-7, 807.e1-2. doi:10.1016/j.otohns.2010.08.008.; 49. Vega-Vázquez MA, Gonzalez-Rodriguez L, Santiago-Rodríguez EJ, Garcés-Domínguez A, Shum LM, et al. Quality of life-in patients with differentiated thyroid cancer at the general endocrinology clinics of the University Hospital of Puerto Rico. Bol Asoc Med P R. 2015 Jan-Mar; 107(1):25-31.; 50. Greenland S. Modeling and variable selection in epidemiologic analysis. American Journal of Public Health. 1989; 79:340 – 349; 51. Goñi E Ignacio, Selt A Guillermo Vander, Ruiz A Catalina, León R Augusto, Solar G Antonieta, Orellana B Pilar. Incidencia de patología salival sintomática alejada en pacientes tratados con yodo radioactivo por cáncer diferenciado de tiroides. Rev Chil Cir 2015; 67(2):153-157. doi:10.4067/S0718-40262015000200007.; 52. Fard-Esfahani A, Emami-Ardekani A, Fallahi B, et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun. 2014;35(8):808-817. doi:10.1097/MNM.0000000000000132.; 53. Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw. 2010 Nov;8(11):1277-86. doi:10.6004/jnccn.2010.0094.; 54. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med. 1998 Sep;39(9):1551-4; 55. Paillahueque G. Efectos secundarios a corto y mediano plazo del tratamiento con 131I en pacientes con cáncer diferenciado de tiroides [Internet]. Santiago, Chile: Universidad de Chile - Facultad de Medicina; 2018 [citado: 2019, noviembre]. Disponible en: http://repositorio.uchile.cl/handle/2250/149434; 56. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009;19(12):1381-1391. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L358195086 http://dx.doi.org/10.1089/thy.2009.1611 http://novacat.nova.edu:4550/resserv?sid=EMBASE&issn=10507256&id=doi:10.1089/thy.2009.1611&atitle=The+benefits+and+risks+of+I-131.; 57. Lu L, Shan F, Li W, Lu H. Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer. Biomed Res Int. 2016; 2016:4376720. doi:10.1155/2016/4376720.; 58. Nostrand D. Side Effects of 131I for Ablation and Treatment of Well-Differentiated Thyroid Carcinoma. In: Wartofsky L, Van Nostrand D (eds). Thyroid Cancer: A Comprehensive Guide to Clinical Management. Humana Press 2006, Totowa, NJ, pp 459–484.; 59. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003 Mar; 13(3):265-71; 60 Clement SC, Peeters RP, Ronckers CM, Links TP, Van den Heuvel-Eibrink MM, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review. Cancer Treat Rev. 2015 Dec; 41(10):925-34. doi:10.1016/j.ctrv.2015.09.001; 61. Rosário PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med. 2008 Nov;49(11):1776-82. doi:10.2967/jnumed.108.050591.; 62. Haraj NE, Bouri H, El Aziz S, Nani S, Habti N, Chadli A. Evaluation of the quality of life in patients followed for differentiated cancer of the thyroid. Ann Endocrinol (Paris) 2019 Feb;80(1):26-31.; 63. Lima E, Ferderle D, Bitencourt A, Vartanian J. Impact of a systematic radioactive iodine therapy protocol for thyroid cancer. Applied Cancer Research. 2013;33(4):180-186.; 64. Taïeb D, Baumstarck-Barrau K, Sebag F, Fortanier C, De Micco C, et al. Heath-related quality of life in thyroid cancer patients following radioiodine ablation. Health Qual Life Outcomes. 2011 May 13;9:33. doi:10.1186/1477-7525-9-33.; http://hdl.handle.net/20.500.12749/7219; instname:Universidad Autónoma de Bucaramanga - UNAB; reponame:Repositorio Institucional UNAB; repourl:https://repository.unab.edu.co

الاتاحة: https://hdl.handle.net/20.500.12749/7219